Dupilumab (Dupixent)
Fundamental treatment for moderate-to-severe atopic dermatitis via IL-4/IL-13 signal blockade
About This Treatment
Dupilumab is a fully humanized monoclonal antibody binding to interleukin-4 receptor alpha (IL-4Rα). By blocking IL-4Rα, it simultaneously suppresses IL-4 and IL-13 signaling, the central Th2 inflammatory pathways. This inhibits Th2 cell differentiation and activation while reducing IgE and IgG4 production, fundamentally improving atopic dermatitis pathophysiology. In moderate-to-severe atopic dermatitis patients, it markedly improves skin inflammation, pruritus, and rash, with many patients achieving remission.
Mechanism of Action
Dupilumab binds IL-4Rα with high affinity, blocking both IL-4 and IL-13 signaling. IL-4/IL-13 are Th2 differentiation factors that simultaneously promote epithelial barrier dysfunction. IL-4Rα blockade suppresses Th2 cell induction and activation while relatively increasing IFN-γ-producing Th1 and IL-17-producing Th17 cells. Additionally, it suppresses IgE production from B cells and reduces mast cell degranulation, alleviating pruritus. Simultaneously, it restores tight junction protein (claudin-1, occludin) expression in epithelial cells, improving skin barrier function.
Indications
Expected Results
Pruritus improves markedly within 2-4 weeks; EASI score decreases >50% by 4-8 weeks. By 12-16 weeks, many patients achieve clear or minimal skin symptoms with expectation of sustained remission with continued treatment.
Clinical Evidence
Risks & Side Effects
Ocular symptoms (conjunctivitis, eyelid dermatitis) reported in 15-30%. Headache and injection site reactions are mild. Increased infection risk is limited but caution warranted in severe infection patients. Pregnancy/lactation experience is limited.
Interested in this treatment?
Start with an AI skin analysis to check your current skin condition